Premium
Effects of a selective partil D 1 agonist, CY 208‐243, in de novo patients with Parkinson disease
Author(s) -
Emre M.,
Rinne U. K.,
Rascol A.,
Lees A.,
Agid Y.,
Lataste X.
Publication year - 1992
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870070309
Subject(s) - bromocriptine , agonist , parkinson's disease , dopamine agonist , medicine , dopamine receptor , dopamine , stimulation , pharmacology , receptor , disease , endocrinology , prolactin , hormone
A selective dopamine D 1 ‐receptor agonist, CY 208‐243, was administered to 23 de novo patients who had had Parkinson disease (PD) for ≤3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D 2 ‐receptor agonist, bromocriptine. Results showed that CY 208‐243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine ≤15 mg to CY 208‐243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D 1 ‐receptor stimulation may result in improvement of motor disability in PD.